Samsung BioLogics began pre-deal investor education in Seoul on Tuesday for a $1.7 billion to $2 billion initial public offering that will tempt investors with the prospect of a new behemoth and potential industry disrupter from one of the world’s most successful tech companies.
¬ Haymarket Media Limited. All rights reserved.
